Cabotegravir + Rilpivirine for HIV Infection
What You Need to Know Before You Apply
What is the purpose of this trial?
This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).
Are You a Good Fit for This Trial?
This trial is for people aged 12 and older with HIV who have had very low virus levels (undetectable) for at least a year, are currently taking daily HIV meds without recent treatment failure, and weigh over 35 kg.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive CAB ULA+RPV ULA or CAB LA+RPV LA
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Trial Overview
The study compares two long-acting injectable combinations—CAB ULA plus RPV ULA versus CAB LA plus RPV LA—in adults and teens with well-controlled HIV to see which works better and is safer.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Participants will receive CAB ULA+RPV ULA.
Participants will receive CAB LA+RPV LA.
Find a Clinic Near You
Who Is Running the Clinical Trial?
ViiV Healthcare
Lead Sponsor
Dr. Harmony Garges
ViiV Healthcare
Chief Medical Officer
MD
Deborah Waterhouse
ViiV Healthcare
Chief Executive Officer since 2017
Bachelor's degree in Business Administration
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.